Market Overview

Pluristem Initiates Final Validation Steps for New Manufacturing Facility


Pluristem Therapeutics (NASDAQ: PSTI) announced today it has initiated the final validation steps for its new "state-of-the-art" manufacturing facility prior to taking possession of the facility. These steps include the validation of several installation systems including as heating, ventilation and air conditioning (HVAC), water, oil free air and sterile room systems.

Zami Aberman, Chairman and CEO of Pluristem commented, "I am extremely proud of our team in meeting milestones for the completion of the world's first commercial cell therapy manufacturing facility. Assuming the PLX cells product candidates are successfully developed and approved by the regulators, we believe that the new facility would have the capacity to produce PLX cells for the treatment of over 150,000 patients annually estimated by Pluristem at $1 billion in production value. Additionally, as clinical trials are approved by regulators for additional indications, our new facility will enable us to supply PLX cells to conduct these trials in parallel."

See full press release

Posted-In: News Guidance Financing Contracts Management Global


Related Articles (PSTI)

View Comments and Join the Discussion!

Partner Center